Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John D Sheppard

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Clinical Ophthalmology (Auckland, N.Z.)|August 21, 2024
Tolerability of Current Treatments for Dry Eye Disease: A Review of Approved and Investigational TherapiesPreeya K Gupta, Rolando Toyos, John D Sheppard, et al.
American Journal of Ophthalmology Case Reports|January 30, 2023
<i>Phialophora chinensis</i> fungal keratitis: An initial case report and species identificationBriana Ply, Connie F Cañete-Gibas, Carmita Sanders, et al.
Ocular Immunology and Inflammation|December 21, 2017
Difluprednate 0.05% versus Prednisolone Acetate 1% for Endogenous Anterior Uveitis: Pooled Efficacy Analysis of Two Phase 3 StudiesJohn D Sheppard, C Stephen Foster, Melissa M Toyos, et al.
Investigative Ophthalmology & Visual Science|November 20, 2010
Lacritin, a novel human tear glycoprotein, promotes sustained basal tearing and is well toleratedSandeep Samudre, Frank A Lattanzio, Victoria Lossen, et al.
American Journal of Ophthalmology|December 13, 2022
Comparison of Persistent Epithelial Defect Treatment With Sutureless Cryopreserved and Dehydrated Amniotic MembraneShawn Sell, Martin de la Presa, Shambhawi Thakur, et al.
Clinical Ophthalmology (Auckland, N.Z.)|March 13, 2019
A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye diseaseMike Taylor, George Ousler, Gail Torkildsen, et al.
American Journal of Ophthalmology|April 1, 2008
Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolatesPenny A Asbell, Kathryn A Colby, Sophie Deng, et al.
Frontiers in Ophthalmology|November 20, 2024
Perfluorohexyloctane ophthalmic solution for dry eye disease: pooled analysis of two phase 3 clinical trialsAhmad M Fahmy, Jennifer S Harthan, David G Evans, et al.
JAMA Ophthalmology|April 6, 2023
Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease: The ESSENCE-2 Randomized Clinical TrialEsen K Akpek, David L Wirta, Johnathon E Downing, et al.
Journal of Cataract and Refractive Surgery|December 26, 2015
Intracameral phenylephrine and ketorolac during cataract surgery to maintain intraoperative mydriasis and reduce postoperative ocular pain: Integrated results from 2 pivotal phase 3 studiesJohn A Hovanesian, John D Sheppard, William B Trattler, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Clinical Ophthalmology (Auckland, N.Z.)|August 21, 2024
Tolerability of Current Treatments for Dry Eye Disease: A Review of Approved and Investigational TherapiesPreeya K Gupta, Rolando Toyos, John D Sheppard, et al.
American Journal of Ophthalmology Case Reports|January 30, 2023
<i>Phialophora chinensis</i> fungal keratitis: An initial case report and species identificationBriana Ply, Connie F Cañete-Gibas, Carmita Sanders, et al.
Ocular Immunology and Inflammation|December 21, 2017
Difluprednate 0.05% versus Prednisolone Acetate 1% for Endogenous Anterior Uveitis: Pooled Efficacy Analysis of Two Phase 3 StudiesJohn D Sheppard, C Stephen Foster, Melissa M Toyos, et al.
Investigative Ophthalmology & Visual Science|November 20, 2010
Lacritin, a novel human tear glycoprotein, promotes sustained basal tearing and is well toleratedSandeep Samudre, Frank A Lattanzio, Victoria Lossen, et al.
American Journal of Ophthalmology|December 13, 2022
Comparison of Persistent Epithelial Defect Treatment With Sutureless Cryopreserved and Dehydrated Amniotic MembraneShawn Sell, Martin de la Presa, Shambhawi Thakur, et al.
Clinical Ophthalmology (Auckland, N.Z.)|March 13, 2019
A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye diseaseMike Taylor, George Ousler, Gail Torkildsen, et al.
American Journal of Ophthalmology|April 1, 2008
Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolatesPenny A Asbell, Kathryn A Colby, Sophie Deng, et al.
Frontiers in Ophthalmology|November 20, 2024
Perfluorohexyloctane ophthalmic solution for dry eye disease: pooled analysis of two phase 3 clinical trialsAhmad M Fahmy, Jennifer S Harthan, David G Evans, et al.
JAMA Ophthalmology|April 6, 2023
Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease: The ESSENCE-2 Randomized Clinical TrialEsen K Akpek, David L Wirta, Johnathon E Downing, et al.
Journal of Cataract and Refractive Surgery|December 26, 2015
Intracameral phenylephrine and ketorolac during cataract surgery to maintain intraoperative mydriasis and reduce postoperative ocular pain: Integrated results from 2 pivotal phase 3 studiesJohn A Hovanesian, John D Sheppard, William B Trattler, et al.
Pageof 6